Lung cancer biomarkers - Where we are and what we need

Cancer Biomarkers

Volumn 6, Issue 3-4, 2009, Pages 221-224

  Stieber, Petra ^a   Holdenrieder, Stefan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

biomarker; CEA; CYFRA 21 1; cytokeratins; guidelines; Lung cancer; NSE; ProGRP; recommendations; serum

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; TUMOR MARKER;

ARTICLE; CANCER SURVIVAL; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; TREATMENT PLANNING; TREATMENT RESPONSE; CHEMISTRY; LUNG NEOPLASMS; ONCOLOGY; TRENDS;

HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 77958173047     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0132     Document Type: Article

References (17)

1. (Anonymous). Tumour markers in lung cancer: EGTM recommendations. European Group on Tumour Markers, Anticancer Res 19 (1999), 2817-2819.
2. V. Barak, S. Holdenrieder, B. Nisman and P. Stieber, Relevance ofcirculating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer, Cancer Biomark 6 (2010), 191-196.
3. M. Fleisher, A. M. Dnistrian, C. M. Sturgeon, R. Lamerz and J. L. Wittliff, Practice guidelines and recommendations for use of tumor markers in the clinic, in: Tumor Markers; Physiology, Pathobiology, Technology, and Clinical Applications, E. P. Diamandis, H. A. Frische, H. Lilja, D. W. Chan and M. K. Schwartz, eds, AACC press 2002, 1st edition, Washington DC, pp. 33-63.
4. S. Holdenrieder, D. Nagel and P. Stieber, Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer, Cancer Biomark 6 (2010), 179-190.
5. A. Jemal, M. J. Thun, L. A. Ries, H. L. Howe, H. K. Weir, M. M. Center, E. Ward, X. C. Wu, C. Eheman, R. Anderson, U. A. Ajani, B. Kohler and B. K. Edwards, Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control, J Natl Cancer Inst 100 (2008), 1672-1694.
6. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun, Cancer statistics, 2009, CA Cancer J Clin 59 (2009), 225-249.
7. D. T. Levy, A. Hyland, C. Higbee, L. Remer and C. Compton, The role of public policies in reducing smoking prevalence in California: results from the California tobacco policy simulation model, Health Policy 82 (2007), 167-185. (Pubitemid 46777059)
8. S. Mallett, A. Timmer, W. Sauerbrei and D. G. Altman, Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines, Br J Cancer 102 (2010), 173-180.
9. R. Molina, S. Holdenrieder, J. M. Auge, A. Schalhorn, R. A. Hatz and P. Stieber, Diagnostic relevance of circulating biomarkers in patients with lung cancer, Cancer Biomark 6 (2010), 163-178.
10. D. M. Parkin, F. Bray, J. Ferlay and P. Pisani, Global Cancer Statistics 2002, CA Cancer J Clin 55 (2005), 74-108.
11. A. Schalhorn, H. Fuerst and P. Stieber, Tumor markers in lung cancer, JLabMed 25 (2001), 353-361.
12. J. Schneider, Detection of lung cancer in silicosis patients using a tumor marker panel, Cancer Biomark 6 (2010), 137-148.
13. B. D. Smith, G. L. Smith, A. Hurria, G. N. Hortobagyi and T. A. Buchholz, Future of cancer incidence in the United States: burdens upon an aging, changing nation, J Clin Oncol 27 (2009), 2758-2765.
14. P. Stieber, R. Hatz, S. Holdenrieder, R. Molina, M. Nap, J. von Pawel, A. Schalhorn, J. Schneider and K. Yamaguchi, National Academy of Clinical Biochemistry Guidelines for the use of tumor markers in lung cancer. In NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic-Lung Cancer (Section 3P). 2006; published online at www.nacb.org/lmpg/ tumor-LMPG-draftPDF.stm.
15. P. Stieber, D. Nagel and V. Heinemann, Tumor markers in metastatic breast cancer: high tumor specificity within the reference range, J Clin Oncol-ASCO Annual Meeting Proceedings 24 (2006), 185.
16. A. Tufman and R. M. Huber, Biological markers in lung cancer: a clinician's perspective, Cancer Biomark 6 (2010), 123-135.
17. J. Watine, B. Friedberg and N. Bouarioua, Biological variables and stratification of patients with inoperable non-small-cell bronchial cancer: recommendations for future trials, Cancer Radiother 6 (2002), 209-216.